A
NBIX icon

AustralianSuper’s Neurocrine Biosciences NBIX Stock Holding History

AustralianSuper’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-62,467
Closed -$6.32M – 293
2023
Q1 		$6.32M Buy
+62,467
New +$6.5M 0.04% 150
2022
Q1 		– Sell
-73,792
Closed -$6.4K – 198
2021
Q4 		$6.4K Sell
73,792
-62,037
-46% -$5.71M 0.03% 176
2021
Q3 		$13M Sell
135,829
-71,451
-34% -$6.75M 0.08% 140
2021
Q2 		$20.2M Buy
207,280
+33,076
+19% +$3.17M 0.14% 98
2021
Q1 		$16.9M Buy
174,204
+139,732
+405% +$14.7M 0.13% 97
2020
Q4 		$3.3M Buy
+34,472
New +$3.33M 0.02% 124

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AustralianSuper's NBIX Position: Q2 2023 in Review

AustralianSuper sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 62,467 shares — an estimated $6.32M sold.

AustralianSuper first reported a position in NBIX in Q4 2020 and held it in 6 quarters. The position peaked at $20.2M in Q2 2021. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • AustralianSuper reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • AustralianSuper sold 62,467 Neurocrine Biosciences shares in Q2 2023, an estimated $6.32M.
  • AustralianSuper first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 6 quarters.
  • AustralianSuper's Neurocrine Biosciences position peaked at $20.2M in Q2 2021.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on AustralianSuper's 13F filing for Q2 2023, filed 28 Jul 2023.